Credit Suisse Starts Adamas Pharmaceuticals (ADMS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 7 | New: 16
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 7 | New: 16
Join SI Premium – FREE
Credit Suisse initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Capstone Copper Corp (CS:CN) (CSFFF) at Equalweight
- Citizens Starts Douglas Elliman Inc. (DOUG) at Market Perform
- Barclays Starts Kaiser Aluminum Corporation (KALU) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
